Euroapi S.A./€EAPI
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Euroapi S.A.
Ticker
€EAPI
Sector
Primary listing
PAR
Industry
Pharmaceuticals
Headquarters
Employees
3,187
ISIN
FR0014008VX5
Website
Euroapi S.A. Metrics
BasicAdvanced
€304M
-
-€1.38
0.65
-
Price and volume
Market cap
€304M
Beta
0.65
52-week high
€4.54
52-week low
€2.26
Average daily volume
136K
Financial strength
Current ratio
2.528
Quick ratio
0.713
Long term debt to equity
1.342
Total debt to equity
7.026
Interest coverage (TTM)
-0.74%
Profitability
EBITDA (TTM)
48.3
Gross margin (TTM)
15.49%
Net profit margin (TTM)
-14.21%
Operating margin (TTM)
-0.91%
Effective tax rate (TTM)
6.45%
Revenue per employee (TTM)
€290,000
Management effectiveness
Return on assets (TTM)
-0.53%
Return on equity (TTM)
-13.67%
Valuation
Price to revenue (TTM)
0.328
Price to book
0.31
Price to tangible book (TTM)
0.32
Price to free cash flow (TTM)
13.707
Free cash flow yield (TTM)
7.30%
Free cash flow per share (TTM)
23.28%
Growth
Revenue change (TTM)
-9.79%
Earnings per share change (TTM)
-31.58%
3-year revenue growth (CAGR)
0.98%
3-year earnings per share growth (CAGR)
148.56%
Bulls say / Bears say
EUROAPI's FOCUS-27 strategic plan aims to achieve an annual incremental Core EBITDA target of €75-80 million by the end of 2027, indicating a strong commitment to enhancing profitability and operational efficiency. (euroapi.com)
The company has secured a €200 million investment from Sanofi, providing substantial financial support to facilitate its transformation and growth initiatives. (fiercepharma.com)
EUROAPI plans to invest between €350 and €400 million in capital expenditures from 2024 to 2027, focusing on strategic growth areas such as Peptides, Oligonucleotides, Vitamin B12, and Prostaglandins, which could drive future revenue growth. (marketscreener.com)
EUROAPI reported a net loss of €189.7 million in 2023, a significant increase from a €15 million loss in 2022, raising concerns about the company's financial stability. (marketscreener.com)
The company anticipates a decline in net sales between 4% and 7% in 2024, primarily due to reduced sales to Sanofi, which could negatively impact revenue streams. (marketscreener.com)
EUROAPI is undergoing significant restructuring, including the sale of two manufacturing sites and a reduction of approximately 550 employees by 2027, which may lead to operational disruptions and associated costs. (fiercepharma.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Euroapi S.A. stock?
Euroapi S.A. (EAPI) has a market cap of €304M as of July 03, 2025.
What is the P/E ratio for Euroapi S.A. stock?
The price to earnings (P/E) ratio for Euroapi S.A. (EAPI) stock is 0 as of July 03, 2025.
Does Euroapi S.A. stock pay dividends?
No, Euroapi S.A. (EAPI) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next Euroapi S.A. dividend payment date?
Euroapi S.A. (EAPI) stock does not pay dividends to its shareholders.
What is the beta indicator for Euroapi S.A.?
Euroapi S.A. (EAPI) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.